Company intelligence / Profile preview

DyAnsys

California, United Statesdyansys.com ↗

Ownership: Private
Development stage: NDA

Overview

DyAnsys has received multiple FDA clearances for its neurostimulation devices. Clinical trials showed significant reductions in pain scores for patients with diabetic neuropathy, with improvements lasting at least 90 days after treatment. For post-cardiac surgery, their device reduced pain scores and decreased the need for analgesics including fentanyl.

Therapeutic areas: CardiovascularPsychiatryEndocrinologyWomen's HealthNeurology
Modalities: Neurostimulation devices
Industry: Therapeutic Medical Devices

Drug pipeline

3 assets

omaveloxolone

NDA

Indications: Friedreich's ataxia

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on DyAnsys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DyAnsys.

Explore the full profile